CSIMarket
 


X4 Pharmaceuticals Inc  (NASDAQ: XFOR)
Other Ticker:  
 


X4 Pharmaceuticals Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics

 



XFOR Gross Profit Margin (Mar 31 2025)
Q1
(Dec 31 2024)
Q4
(Sep 30 2024)
Q3
(Jun 30 2024)
Q2
(Mar 31 2024)
Q1
Y / Y Revenue Change - - - - -
Seq. Revenue Change 1908.86 % 156.07 % -0.53 % - -
Revenue In Millions $28.81 $1.43 $0.56 $0.56 $0.00
Gross Profit Margin 83.63 % 78.94 % 59.46 % 52.4 % -
Gross Profit Margin Total Ranking # 1181 # 1427 # 2076 # 2335 #
Gross Profit In Millions $24.09 $1.13 $0.33 $0.30 $0.00
Y / Y Gross Profit Change - - - - -
Seq. Gross Profit Change 2028.18 % 239.94 % 12.88 % - -


Commenting First Quarter 2025 Gross Profit Margin
X4 Pharmaceuticals Inc Gross Profit grew by 2028.18 % in Q1 sequentially to 24 millions, while Revenue increased by 1908.86 %, this led to improvement in the company's Gross Profit Margin to 83.63 %, above the X4 Pharmaceuticals Inc average Gross Profit Margin.


Observing first quarter 2025 results within Biotechnology & Pharmaceuticals industry 49 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1181, from total ranking in the previous quarter at 1427.
Learn about Gross Margin
XFOR's Gross Profit Margin first quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 50
Healthcare Sector # 264
Overall # 1179

Gross Profit Margin Statistics
High Average Low
100 % 79.07 % 52.4 %
(Mar 31 2020)   (Jun 30 2024)




Other Gross Profit Margin Profitability Ratios
XFOR's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
XFOR's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for XFOR's Competitors
Gross Profit Margin Profit Margin for X4 Pharmaceuticals Inc's Suppliers
Gross Profit Margin Profit Margin for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Gross Profit Growth
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginMar 31 2025 MRQ Gross ProfitMar 31 2025 MRQ Revenue
Arcellx Inc   100.00 %$ 8.129  Millions$ 8.129  Millions
Alector Inc   100.00 %$ 3.674  Millions$ 3.674  Millions
Aligos Therapeutics Inc   100.00 %$ 0.311  Millions$ 0.311  Millions
Atara Biotherapeutics Inc   100.00 %$ 98.385  Millions$ 98.385  Millions
Black Diamond Therapeutics Inc   100.00 %$ 70.000  Millions$ 70.000  Millions
C4 Therapeutics Inc   100.00 %$ 7.238  Millions$ 7.238  Millions
Cg Oncology Inc   100.00 %$ 0.052  Millions$ 0.052  Millions
Caribou Biosciences Inc   100.00 %$ 2.353  Millions$ 2.353  Millions
Cardiff Oncology Inc   100.00 %$ 0.109  Millions$ 0.109  Millions
Curis Inc   100.00 %$ 2.380  Millions$ 2.380  Millions
Crispr Therapeutics Ag  100.00 %$ 0.865  Millions$ 0.865  Millions
Dbv Technologies S a   100.00 %$ 0.753  Millions$ 0.753  Millions
Editas Medicine Inc   100.00 %$ 4.658  Millions$ 4.658  Millions
Enzon Pharmaceuticals inc   100.00 %$ 0.497  Millions$ 0.497  Millions
Fate Therapeutics Inc   100.00 %$ 1.629  Millions$ 1.629  Millions
4d Molecular Therapeutics Inc   100.00 %$ 0.014  Millions$ 0.014  Millions
Fennec Pharmaceuticals Inc   100.00 %$ 8.751  Millions$ 8.751  Millions
Monte Rosa Therapeutics Inc   100.00 %$ 84.929  Millions$ 84.929  Millions
Inmune Bio Inc  100.00 %$ 0.050  Millions$ 0.050  Millions
Century Therapeutics inc   100.00 %$ 109.164  Millions$ 109.164  Millions
Invivyd Inc   100.00 %$ 11.304  Millions$ 11.304  Millions
Krystal Biotech Inc   100.00 %$ 88.183  Millions$ 88.183  Millions
Kymera Therapeutics Inc   100.00 %$ 22.100  Millions$ 22.100  Millions
Meiragtx Holdings Plc  100.00 %$ 1.926  Millions$ 1.926  Millions
Metagenomi Inc   100.00 %$ 4.127  Millions$ 4.127  Millions
Ocugen Inc   100.00 %$ 1.481  Millions$ 1.481  Millions
Prime Medicine Inc   100.00 %$ 1.454  Millions$ 1.454  Millions
Prokidney Corp   100.00 %$ 0.230  Millions$ 0.230  Millions
Regenxbio Inc   100.00 %$ 89.012  Millions$ 89.012  Millions
Relay Therapeutics Inc   100.00 %$ 7.679  Millions$ 7.679  Millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com